Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,350 shares of the stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $22.15, for a total value of $74,202.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Benjamin Hohl also recently made the following trade(s):
- On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
- On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50.
- On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total transaction of $178,500.00.
- On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
- On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
- On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
Enliven Therapeutics Stock Performance
Shares of ELVN stock traded up $0.11 on Tuesday, hitting $22.50. 90,373 shares of the company's stock traded hands, compared to its average volume of 252,244. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.84 and a beta of 1.02. The company's fifty day simple moving average is $25.33 and its 200 day simple moving average is $24.29. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC raised its holdings in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics during the third quarter worth about $256,000. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics in the third quarter worth about $271,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Enliven Therapeutics in the second quarter worth about $322,000. 95.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several brokerages have recently commented on ELVN. Robert W. Baird boosted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $38.25.
Check Out Our Latest Report on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
